Mine GAYAF, Nimet AKSEL, Ahmet Emin ERBAYCU, Hakan KOPORAL, Ceyda ANAR

Relationship between 18F-FDG PET/CT radiometabolic markers and EGFR mutation, positive ALK Expression in patients with non-small cell lung cancer

Relationship between 18F-FDG PET/CT radiometabolic markers and EGFR mutation, positive ALK Expression in patients with non-small cell lung cancer Introduction: The aim of this study was to evaluate the association between the presence of EGFR mutations, ALK rearrangement and the standardized uptake value (SUV) of 18F-fluoro-2-deoxy-glucose (18F-FDG) by PET/CT imaging in patients with NSCLC. Materials and Methods: We retrospectively reviewed NSCLC patients, who underwent EGFR mutation, ALK rearrangement testing and pre-treatment PET/ CT. The relationships of EGFR mutation, ALK rearrangement with patient characteristics and three parameters based on 18F-FDG PET/CT, including the maximal standard uptake value (SUVmax) of the primary tumour (tSUVmax), lymph node (nSUVmax) and distant metastasis (mSUVmax) were evaluated. Results: EGFR mutations were found more frequently in females and nonsmokers. tSUVmax was the only PET parameter that was lower in EGFRpositive patients than in EGFR-negative patients (8.7 vs. 11), with a p value of 0.032. There were no differences between nSUVmax and mSUVmax results and EGFR mutation. tSUVmax, nSUVmax and mSUVmax were not significantly different between ALK positive and ALK negative groups in NSCLC. The presence of pleural fluid at the time of diagnosis was significantly associated with positive ALK expression. Conclusion: We showed that low tSUVmax and primary tumour diameter were associated with mutant EGFR status and could be evaluated with other clinical factors to increase the discrimination in EGFR mutation status in some NSCLC patients without EGFR testing. There is a correlation between ALK positivity and the presence of pleural fluid. We also noted that the ALK positivity might be only in the adenocarcinoma group and at a younger age.

PDF

___

1. Karapolat İ. FDG PET/CT Imaging to Evaluate Treatment Response in Lung Cancer. Nucl Med Semin 2018: 43-51.

2. Oyan B. Targetted Therapies in Lung Cancer. Turkiye Klinikleri J Med Oncol-Special Topics 2016: 9(2): 1-13.

3. Heist RS, Sequist LV, Pujol JL. Genetic changes in squamous cell lung cancer. A review. J Thoracic Oncology 2012; 7: 924-33.

4. Shaw AT, Kim DW, Nakagawa K, Seto T, Crinó L, Ahn MJ, et al. Crizotinib versus chemotherapy in advanced ALKpositive lung cancer. N Engl J Med 2013; 368: 2385-94.

5. Lindeman NI, Cagle PT, Beasley MB, Chitale DA, Sanja D, Giuseppe G et al. Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. J Mol Diagnostics: JMD 2013; 15: 415-53.

6. Leighl NB, Rekhtman N, Biermann WA, Huang A, MinoKenudson M, Suresh SR et al. Molecular testing for selection of patients with lung cancer for epidermal growth factor receptor and anaplastic lymphoma kinase tyrosine kinase inhibitors: American Society of Clinical Oncology endorsement of the College of American Pathologists/ international association for the study of lung cancer/ association for molecular pathology guideline. J ClinOncol: Off J Am Soc Clin Oncol 2014; 32: 3673-9.

7. Makinoshima H, Takita M, Matsumoto S, Yagishit T, Satoshi O, Hiroyasu E et al. Epidermal growth factor receptor (EGFR) signaling regulates global metabolic pathways in EGFR-mutated lung adenocarcinoma. J Biol Chem 2014; 289: 20813-23.

8. Lv Z, Fan J, Xu J, Wu F, Huang Q, Guo M et al. Value of 18F-FDG PET/CT for predicting EGFR mutations and positive ALK expression in patients with non-small cell lung cancer: a retrospective analysis of 849 Chinese patients. European Journal of Nuclear Medicine and Molecular Imaging 2018; 45: 735-50.

9. Guan J, Xiao NJ, Chen M, Wen LZ, Zhang YW, Wang S, et al. 18F-FDG uptake for prediction EGFR mutation status in non-small cell lung cancer. Medicine 2016; 95(30):e4421.

10. De Rosa V, Iommelli F, Monti M, Fonti R, Votta G, Stoppelli MP, et al. Reversal of Warburg effect and reactivation of oxidative Phosphorylation by differential inhibition of EGFR signaling pathways in non-small cell lung cancer. Clin Cancer Res: Off J Am Assoc Cancer Res 2015; 21:5110-20.

11. Mak RH, Digumarthy SR, Muzikansky A, Engelman JA, Shepard JAO, et al. Role of 18F-fluorodeoxyglucose positron emissiontomography in predicting epidermal growth factor receptor mutations in non-small cell lung cancer. Oncologist 2011; 16: 319-26.

12. Lee EY, Khong PL, Lee VH, Qian W, Yu X, Wong MP. Metabolic phenotype of stage IV lung adenocarcinoma: relationship with epidermal growth factor receptor mutation. Clin Nucl Med 2015; 40: e190-5.

13. Huang CT, Yen RF, Cheng MF, Hsu YC, Wei PF, Tsai YJ, et al. Correlation of F-18 fluorodeoxyglucose-positron emission tomography maximal standardized uptake value and EGFR mutations in advanced lung adenocarcinoma. Med Oncol 2010; 27: 9-15.

14. Kanmaz ZD, Aras G, Tuncay E, Bahadır A, Kocatürk C, Yaşar ZA, et al. Contribution of 18 Fluorodeoxyglucose positron emission tomography uptake and TTF-1 expression in the evaluation of the EGFR mutation in patients with lung adenocarcinoma. Cancer Biomarkers: Section A Dis Markers 2016; 16: 489-98.

15. Choi H, Paeng JC, Kim DW, Lee JK, Park CM, Kang KW, et al. Metabolic and metastatic characteristics of ALKrearranged lung adenocarcinoma on FDG PET/CT. Lung Cancer 2013; 79: 242-7.

16. Na II, Byun BH, Kim KM, Cheon GJ, Choe DH, Koh JS, et al.18F-FDG uptake and EGFR mutations in patients with non-smallcell lung cancer: a single-institution retrospective analysis. Lung Cancer 2010; 67: 76-80.

17. Cho A, Hur J, Moon YW, Hong SR, Suh YJ, Kim YJ et al. Correlation between EGFR gene mutation, cytologic tumor markers, 18F-FDG uptake in non-small cell lung cancer. BMC Cancer 2016; 16:224.

18. Ko KH, Hsu HH, Huang TW, Gao HW, Shen DH, Chang WC, et al. Value of 18F-FDG uptake on PET/CT and CEA level to predict epidermal growth factor receptor mutations in pulmonary adenocarcinoma. Eur J Nucl Med Mol Imaging 2014; 41: 1889-97.

19. PaoW, Miller V, Zakowski M, Doherty J, Politi K, Sarkaria I et al. EGFR receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci U S A. 2014; 101: 13306-11.

20. Soda M, Choi YL, Enomoto M, Takada S, Yamashita Y, Ishikawa S, et al. Identification of the transforming EML4- ALK fusion gene in non-small-cell lung cancer. Nature 2007; 448: 561-6.

21. Inamura K, Takeuchi K, Togashi Y, Nomura K, Ninomiya H, Okui M, et al. EML4- ALK fusion is linked to histological characteristics in a subset of lung cancers. J Thorac Oncol 2008; 3:13-7.

22. Jeong CJ, Lee HY, Han J, Jeong JY, Lee KS, Choi YL, et al. Role of imaging biomarkers in predicting anaplastic lymphoma kinasepositive lung adenocarcinoma. Clin Nucl Med 2015; 40: e34-9.

23. Fukui T, Yatabe Y, Kobayashi Y, Tomizawa K, Ito S, Hatooka S et al. Clinico radiologic characteristics of patients with lung adenocarcinoma harboring EML4-ALK fusion oncogene. Lung Cancer 2012; 77: 319-25.

24. Park EA, Lee HJ, Kim YT, Kang CH, Kang KW, Jeon YK, et al. EGFR gene copy number in adenocarcinoma of the lung by FISH analysis: investigation of significantly related factors on CT,FDG-PET, and histopathology. Lung Cancer 2009; 64: 179-8.

25. Okada M, Tauchi S, Iwanaga K, Mimura T, Kitamura Y, Watanabe H, et al. Associations among bronchioloalveolar carcinoma components, positron emission tomographic and computed tomographic findings, and malignant behavior in small lung adenocarcinomas. J Thorac Cardiovasc Surg 2007; 133: 1448-54.